Sensei Biotherapeutics

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced it will present two posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held in Boston, MA from November 8 - 12, 2022.

Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

- SNS-101 demonstrated a favorable pharmacokinetic profile, enhanced anti-tumor effects in combination with anti-PD-1 antibodies and a significantly improved cytokine release profile as compared to a pH-independent VISTA antibody

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced it will present additional preclinical data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, being held September 28 – October 1, 2022 at the New York Hilton Midtown in New York, New York.

Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

BOSTON, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today reported preliminary preclinical data from mouse and non-human primate studies of SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).

Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody

- SNS-101 pre-IND feedback received from FDA with program on track for IND filing in first half of 2023 -

Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer, today announced the appointment of Patrick Gallagher, MBA, MPH, as chief business officer.

Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer

BOSTON, May 25, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, president and chief executive officer, will present at the Jefferies Healthcare Conference, being held in New York, NY and virtually, on Wednesday, June 8, 2022 at 3:00 p.m. ET.

Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference

- SNS-101 preclinical data provide encouraging validation of pH-sensitive approach to inhibiting VISTA with high selectivity to treat solid tumors -

Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

- Reported preclinical proof of concept data from TMAb platform demonstrating potent and selective pH-dependent binding to “active” VISTA -

Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights

Brings decades of both board and management life sciences experience Brings decades of both board and management life sciences experience

Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that company management will participate in the 32 nd Annual Oppenheimer Healthcare Conference, taking place virtually March 15-17, 2022.

Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference

Charles & Colvard

Crexendo, Inc.

Doma Holdings

Symbolic Logic, Inc.

The economic sentiment indicator in the Eurozone rose to a 3-month high level of 114 in February, surpassing market estimates of 113.1. Investors, meanwhile, focused on some notable insider trades When insiders purchase or sell shares, it indicates their confidence or concern around the company.

Executives Buy Around $1M Of 5 Penny Stocks

IMARA

US Xpress Enterprises

Insiders are scooping up these penny stocks in February. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 3 To Watch With Insider Buying In February

BOSTON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that company management will participate in Citi's 2022 Immuno-Oncology Summit.

Sensei Biotherapeutics to Participate in Citi's 2022 Virtual Immuno-Oncology Summit

Company names Erin Colgan as chief financial officer and Robert Pierce, M.D. as chief R&D officer Company names Erin Colgan as chief financial officer and Robert Pierce, M.D. as chief R&D officer

Sensei Biotherapeutics Announces Executive Promotions

BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it has won a Comparably award for 2021 “Best CEOs.”

Sensei Biotherapeutics Named a Winner of Comparably's Best CEO Award

BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it was added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to market open on Monday, December 20, 2021.

Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index

BOSTON, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced its participation in a fireside chat during the Piper Sandler 33rd Annual Virtual Healthcare conference being held from November 29 to December 2, 2021.

Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference

V-domain Ig-containing suppressor of T-cell activation (VISTA) is a novel immune checkpoint protein that has been recognized as an important potential immunotherapeutic target

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

- SNS-101 identified as a tumor-selective anti-VISTA antibody product candidate from  TMAb platform -

Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights

BOSTON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, president and chief executive officer, will participate in a fireside chat at the Berenberg virtual U.S. CEO Conference on Tuesday, November 9 at 10:00 a.m. EST.

Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on Tuesday, November 9, 2021

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it will present preclinical data for its anti-VISTA (V-domain Ig suppressor of T cell activation) product candidate, SNS-101, during the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held in Washington, D.C. from November 10 - 14, 2021. These data are the first preclinical data to be presented by Sensei Bio in a scientific forum from the company's TMAb (Tumor Microenvironment Activated biologics) platform.

Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Sensei Biotherapeutics, Inc. (SNSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sensei Biotherapeutics, Inc. (SNSE) Upgraded to Buy: Here's Why

- Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti-tumor activity in combination with PD-1 blockade in a human VISTA knock-in mouse model –

Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program

BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointment of Kristian Humer, former managing director of Banking, Capital Markets & Advisory for the Global Healthcare team at Citigroup, Inc. as an independent director to the company's board of directors, effective July 30, 2021.

News for Sensei Biotherapeutics Stock (SNSE)